

SCIENTIFIC AND MEDICAL EQUIPMENT HOUSE COMPANY
(A SAUDI JOINT STOCK COMPANY)

INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
AND INDEPENDENT AUDITOR'S REVIEW REPORT
FOR THE THREE- MONTH AND THE SIX-MONTH PERIODS ENDED 30 JUNE 2025

**SCIENTIFIC AND MEDICAL EQUIPMENT HOUSE COMPANY
(A SAUDI JOINT STOCK COMPANY)
INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
AND INDEPENDENT AUDITOR'S REVIEW REPORT
FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED 30 JUNE 2025**

INDEX	PAGE
Independent auditor's review report on the interim financial information	1
Interim condensed consolidated statement of financial position	2
Interim condensed consolidated statement of profit or loss and other comprehensive income	3
Interim condensed consolidated statement of changes in equity	4
Interim condensed consolidated statement of cash flows	5
Notes to the interim condensed consolidated financial statements	6 - 16

**Independent Auditor's Review Report on the Interim Financial information
To The Shareholders of Scientific and Medical Equipment House Company
(A Saudi Joint Stock Company)**

Introduction


We have reviewed the accompanying interim condensed consolidated statement of financial position of Scientific and Medical Equipment House Company, A Saudi Joint Stock Company (the "Company") and its subsidiaries (collectively referred to as "Group") as at 30 June 2025, and the related interim condensed consolidated statements of profit or loss and other comprehensive income for the three-month and six month periods ended 30 June 2025, and the related statements of changes in equity and cash flows for the six-month period then ended, and other explanatory notes. Management is responsible for the preparation and presentation of this interim financial information in accordance with International Accounting Standard 34, "Interim Financial Reporting" ("IAS 34") that is endorsed in the Kingdom of Saudi Arabia. Our responsibility is to express a conclusion on this interim financial information based on our review.

We conducted our review in accordance with the International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", that is endorsed in the Kingdom of Saudi Arabia. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing that are endorsed in the Kingdom of Saudi Arabia and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim financial information is not prepared, in all material respects, in accordance with IAS 34 as endorsed in the Kingdom of Saudi Arabia.

For and on behalf of Alluhaid and Alyahya Chartered Accountants




Saleh A. Al-Yahya
Certified Public Accountant
License No. 473


Riyadh: 19 Safar 1447H
(13 August 2025)



SCIENTIFIC AND MEDICAL EQUIPMENT HOUSE COMPANY
(A SAUDI JOINT STOCK COMPANY)
INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 30 JUNE 2025

	Notes	30 June 2025 SAR (Unaudited)	31 December 2024 SAR (Audited)
ASSETS			
Non-current assets			
Property, plant, and equipment		28,522,246	29,789,154
Right-of-use assets		16,099,312	16,449,700
Investment properties		31,053,645	31,226,545
Intangible assets		896,230	971,000
Prepayments and other debit balances non-current portion		3,108,558	3,108,558
Total non-current assets		79,679,991	81,544,957
Current assets			
Inventories		68,938,828	103,207,010
Trade receivables and contract assets	5	689,800,919	587,148,702
Prepayments and other debit balances		82,315,273	66,260,065
Due from related parties	6a	35,080,288	25,539,825
Cash and cash equivalents		27,274,759	88,064,217
Total current assets		903,410,067	870,219,819
TOTAL ASSETS		983,090,058	951,764,776
EQUITY AND LIABILITIES			
EQUITY			
Share capital	7	300,000,000	300,000,000
Statutory reserve		36,586,165	36,586,165
Retained earnings		194,081,957	174,021,556
Equity attributable to the shareholders of the Parent Company		530,668,122	510,607,721
Non-controlling interests		(6,611,489)	(5,619,787)
TOTAL EQUITY		524,056,633	504,987,934
LIABILITIES			
Non-current liabilities			
Employees' defined benefits obligations		69,639,717	70,078,886
Lease liabilities		9,160,462	9,011,392
Long-term borrowings	8	5,900,000	6,775,000
Total non-current liabilities		84,700,179	85,865,278
Current liabilities			
Lease liabilities – current portion		5,458,788	5,677,668
Long-term borrowings - current portion	8	1,650,000	1,550,000
Short-term borrowings	8	172,324,799	185,138,364
Trade payables		50,004,600	56,251,385
Accrued expenses and other credit balances		103,713,459	87,038,781
Due to related parties	6b	2,026,953	-
Contract liabilities		16,713,566	10,243,328
Zakat payable		22,441,081	15,012,038
Total current liabilities		374,333,246	360,911,564
TOTAL LIABILITIES		459,033,425	446,776,842
TOTAL EQUITY AND LIABILITIES		983,090,058	951,764,776


Chairman of the Board of Directors
Mr. Basil Bin Saud Al-Arifi


Chief Executive Officer
Mr. Faisal bin Hawas Al-Atawi



Chief Financial Officer
Mr. Yasser Ahmed El-Safadi


The accompanying notes form an integral part of these interim condensed consolidated financial statements.

SCIENTIFIC AND MEDICAL EQUIPMENT HOUSE COMPANY
(A SAUDI JOINT STOCK COMPANY)
INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER
COMPREHENSIVE INCOME (UNAUDITED)
FOR THE THREE-MONTH AND THE SIX-MONTH PERIODS ENDED 30 JUNE 2025

	Notes	Three-month period ended		Six-month period ended	
		30 June 2025 SAR	30 June 2024 SAR	30 June 2025 SAR	30 June 2024 SAR
Continuing operations:					
Revenue	12	272,036,178	215,444,254	494,268,190	431,620,024
Cost of revenue	12	(233,293,595)	(180,504,607)	(421,760,746)	(359,317,432)
Gross profit		38,742,583	34,939,647	72,507,444	72,302,592
Selling and marketing expenses		(5,657,916)	(4,077,971)	(11,039,484)	(8,278,926)
General and administrative expenses		(15,735,292)	(15,126,407)	(30,352,789)	(30,300,694)
(Charge for) / reversal of expected credit losses	5	(1,350,000)	1,851,837	(847,217)	962,025
Operating profit		15,999,375	17,587,106	30,267,954	34,684,997
Finance cost		(3,762,889)	(5,942,265)	(7,494,374)	(13,906,401)
Other income	9	4,383,057	2,459,652	5,968,870	7,493,028
Profit before zakat from continuing operations		16,619,543	14,104,493	28,742,450	28,271,624
Zakat for the period		(4,844,899)	(3,346,311)	(9,673,751)	(6,509,885)
Net profit for the period from continuing operations		11,774,644	10,758,182	19,068,699	21,761,739
Discontinued operations:					
Net loss for the period from discontinued operation	1	-	(3,404,228)	-	(6,108,830)
Net profit for the period		11,774,644	7,353,954	19,068,699	15,652,909
Other comprehensive income		-	-	-	-
Total comprehensive income for the period		11,774,644	7,353,954	19,068,699	15,652,909
Net profit / (loss) for the period attributable to:					
Shareholders of the parent company		12,371,320	7,661,663	20,060,401	16,428,903
Non-controlling interests		(596,676)	(307,709)	(991,702)	(775,994)
		11,774,644	7,353,954	19,068,699	15,652,909
Net profit / (loss) attributable to shareholders arises from:					
Continuing operations		12,371,320	11,031,849	20,060,401	22,476,645
Discontinued operations		-	(3,370,186)	-	(6,047,742)
		12,371,320	7,661,663	20,060,401	16,428,903
Total comprehensive income for the period attributable to:					
Shareholders of the parent company		12,371,320	7,661,663	20,060,401	16,428,903
Non-controlling interests		(596,676)	(307,709)	(991,702)	(775,994)
		11,774,644	7,353,954	19,068,699	15,652,909
Basic and diluted earnings per share attributable to the shareholders of the parent company:					
From continuing operations		0.41	0.37	0.67	0.75
From discontinued operations		-	(0.11)	-	(0.20)
Total	10	0.41	0.26	0.67	0.55


Chairman of the Board of Directors
Mr. Basil Bin Saud Al-Arifi


Chief Executive Officer
Mr. Faisal bin Hawas Al-Atawi



Chief Financial Officer
Mr. Yasser Ahmed El-Safadi


The accompanying notes form an integral part of these interim condensed consolidated financial statements.

SCIENTIFIC AND MEDICAL EQUIPMENT HOUSE COMPANY
(A SAUDI JOINT STOCK COMPANY)
INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (UNAUDITED)
FOR THE SIX-MONTH PERIOD ENDED 30 JUNE 2025

	Attributable to the shareholders of the parent				Non-controlling interests	Total equity
	Share capital SAR	Statutory reserve SAR	Retained earnings SAR	Total SAR	SAR	SAR
As at 1 January 2024 (Audited)	300,000,000	36,586,165	174,180,026	510,766,191	(3,998,442)	506,767,749
Net profit for the period	-	-	16,428,903	16,428,903	(775,994)	15,652,909
Other comprehensive income for the period	-	-	-	-	-	-
Total comprehensive income for the period	-	-	16,428,903	16,428,903	(775,994)	15,652,909
As at 30 June 2024 (Unaudited)	300,000,000	36,586,165	190,608,929	527,195,094	(4,774,436)	522,420,658
As at 1 January 2025 (Audited)	300,000,000	36,586,165	174,021,556	510,607,721	(5,619,787)	504,987,934
Net profit for the period			20,060,401	20,060,401	(991,702)	19,068,699
Other comprehensive income for the period			-	-		-
Total comprehensive income for the period	-	-	20,060,401	20,060,401	(991,702)	19,068,699
As at 30 June 2025 (Unaudited)	300,000,000	36,586,165	194,081,957	530,668,122	(6,611,489)	524,056,633


Chairman of the Board of Directors
Mr. Basil Bin Saud Al-Arifi


Chief Executive Officer
Mr. Faisal bin Hawas Al-Atawi



Chief Financial Officer
Mr. Yasser Ahmed El-Safadi


The accompanying notes form an integral part of these interim condensed consolidated financial statements.

SCIENTIFIC AND MEDICAL EQUIPMENT HOUSE COMPANY
(A SAUDI JOINT STOCK COMPANY)
INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (UNAUDITED)
FOR THE SIX-MONTH PERIOD ENDED 30 JUNE 2025

	Six-month period ended	
	30 June 2025	30 June 2024
	SAR	SAR
OPERATING ACTIVITIES		
Profit before zakat from continuing operations	28,742,450	28,271,624
Loss before zakat from discontinued operations	-	(6,108,830)
Profit before zakat	28,742,450	22,162,794
Adjustments for non-cash items:		
Depreciation of property, plant and equipment	5,117,137	5,549,053
Depreciation of investment properties	172,900	172,900
Depreciation of right-of-use assets	4,410,158	4,588,485
Amortization of intangible assets	74,770	215,480
Charge for / (Reversal) of expected credit losses	847,217	(962,025)
Provision for slow-moving inventories	1,533,891	900,000
(Gain) / loss on disposal of property, plant and equipment	(217,899)	506,070
Loss on terminated leases contracts	-	148,582
Loss on disposal of intangible assets	-	826,100
Finance cost	7,494,374	13,906,401
Employees' defined benefits obligation	8,144,823	8,711,731
	56,319,821	56,725,571
Changes in working capital:		
(Increase) / decrease in trade receivables and contract assets	(103,499,434)	62,107,866
Decrease / (increase) in inventories	32,734,291	(13,356)
(Increase) / decrease in prepayments and other debit balances	(16,055,208)	12,000,745
Decrease in trade payables	(6,246,785)	(5,392,391)
Increase in accrued expenses and other credit balances	16,674,678	9,018,276
Increase in contract liabilities	6,470,238	4,617,327
(Increase) / decrease in due from / to related parties, net	(7,513,510)	882,291
	(21,115,909)	139,946,329
Employees' defined benefits obligation paid	(8,583,992)	(4,197,919)
Zakat paid	(2,244,708)	(3,106,443)
Net cash flows (used in) / provided by operating activities	(31,944,609)	132,641,967
INVESTING ACTIVITIES		
Purchase of property, plant, and equipment	(3,936,355)	(1,959,550)
Proceeds from disposal of property, plant, and equipment	304,025	1,427,971
Net cash flows used in investing activities	(3,632,330)	(531,579)
FINANCING ACTIVITIES		
Notes payable	-	(12,729,229)
Payment of principal portion of lease liabilities	(4,681,746)	(5,705,785)
Repayments of long-term borrowings	(775,000)	(625,000)
Proceeds from short-term borrowings	224,077,617	448,228,212
Repayments of short-term borrowings	(236,891,182)	(535,458,122)
Financing costs paid	(6,942,208)	(13,364,242)
Net cash flows used in financing activities	(25,212,519)	(119,654,166)
Net (decrease) / increase in cash and cash equivalents	(60,789,458)	12,456,222
Cash and cash equivalents at beginning of the period	88,064,217	16,947,670
Cash and cash equivalents at the end of the period	27,274,759	29,403,892
Non-cash transactions		
Additions to right-of-use assets against lease liabilities	4,059,770	3,328,011
Termination of right-of-use assets against lease liabilities	-	(3,183,384)


Chairman of the Board of Directors
Mr. Basil Bin Saud Al-Arifi


Chief Executive Officer
Mr. Faisal bin Hawas Al-Atawi


Chief Financial Officer
Mr. Yasser Ahmed El-Safadi

The accompanying notes form an integral part of these interim condensed consolidated financial statements.

SCIENTIFIC AND MEDICAL EQUIPMENT HOUSE COMPANY

(A SAUDI JOINT STOCK COMPANY)

**NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
FOR THE THREE AND SIX-MONTH PERIOD ENDED 30 JUNE 2025****1. ORGANIZATION AND ACTIVITY**

Scientific and Medical Equipment House Company (the "Company" or "Parent Company") is a Saudi joint stock company, under Commercial Registration No. 1010166664, issued in Riyadh dated 3 Rabi' Al- Awwal 1422 H (corresponding to 26 May 2001).

The Company is licensed to engage in general contracting of buildings, roads, bridges, electrical, electronic and mechanical works, dams, roads and bridges, maintaining, cleaning, managing and operating of medical centers, cities' cleanliness, maintaining and operating of industrial, water and sewage works, maintenance of scientific and medical equipment, wholesale and retail trade in medical, laboratorial and scientific equipment and its accessories, import and export services, and catering services.

The registered address of the Company is P.O. Box 1584, Riyadh 11441, Kingdom of Saudi Arabia.

The accompanying interim condensed consolidated financial statements include the assets and liabilities of the Company and its branches listed below, where the Company is also operating under sub-commercial registrations:

Commercial registration number	Commercial name	City	Registration date	Activity
1010228685	Scientific and Medical Equipment House Company for Contracting	Riyadh	01/02/1428H	General contracting for buildings, roads and bridges.
1010358380	Scientific and Medical Equipment House Company	Riyadh	06/02/1434H	Operating restaurants, supplying, cooking, serving nutrition services and trading foodstuffs.
1010358386	Scientific and Medical Equipment House Company	Riyadh	06/02/1434H	Sale of safety equipment, installation and maintenance of firefighting and fire alarms equipment, filling and maintenance of fire extinguishers.
1010399879	Scientific and Medical Equipment House Company	Riyadh	27/02/1435H	Importing, selling, installation and maintenance of security surveillance cameras, security detectors, inspection and burglar alarm devices.
1010608122	Scientific and Medical Equipment House Company for Private Civil Security Guards	Riyadh	11/08/1438H	Providing a private civil security guard service.
1010613686	Scientific and Medical Equipment House Company	Riyadh	26/03/1439H	Maintenance and operation contracting.
1010636049	Al-Biruni Medical Industries Co.	Riyadh	26/09/1441H	Manufacture of ordinary radiological equipment, tubes, devices and its accessories for medical, scientific and research purposes, including (X-rays, beta rays, gamma rays).
1010653676	Scientific and Medical Equipment House Company	Riyadh	27/01/1442H	Medical operating of hospitals.
1010653677	Scientific and Medical Equipment House Company	Riyadh	27/01/1442H	Repairing and maintenance of radiological, electronic, medical and therapeutic equipment, cleaning services for governmental buildings, building maintenance services activities.
1009081998	Scientific and Medical Equipment House Company	Riyadh	02/02/1446H	Land freight for goods.

SCIENTIFIC AND MEDICAL EQUIPMENT HOUSE COMPANY

(A SAUDI JOINT STOCK COMPANY)

**NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
FOR THE THREE AND SIX-MONTH PERIOD ENDED 30 JUNE 2025 (CONTINUED)****1. ORGANIZATION AND ACTIVITY (Continued)**

The interim condensed consolidated financial statements include the financial information of the Company and its subsidiaries (collectively referred to as the “Group”), The subsidiaries listed below are limited liability companies registered in the Kingdom of Saudi Arabia:

Company's name	Ownership % as at		Activity
	30 June 2025	31 December 2024	
Girgas Trading Co. Drug Store Co. (A)	100%	100%	A warehouse for wholesale and retail trade in medical supplies.
Protecta Visions Co.	100%	100%	Import, export, wholesale and retail trade in medical, electronical, electrical and mechanical equipment and devices, laundries, incinerator equipment and pumps.
Nabd Medical Industries Co.	51%	51%	Manufacture of pacemakers, manufacture of ECG devices, manufacture of tubes for catheterization, nutrition and liposuction, etc.
Alwateen A/C & Refrigeration Co.	100%	100%	Cooling and air conditioning systems installation, maintenance and repair.
New Era Co. Ltd.	100%	100%	Installation and extension of television, satellite, computer and telecommunications networks. Installation and maintenance of fire alarm, security and lighting systems and equipment. Extension of electrical and communication wires.
Future Doors Contracting Co.	100%	100%	Installation and maintenance of cooling, air conditioning, electric, gas and oil heating systems. Extension and maintenance of gas, steam and fire pipes. Installation, extension and maintenance of air conditioning and irrigation pipes.
The House of Food Supplies Co.	100%	100%	Refrigerated food warehouses, wholesale of food and drinks

(A) Girgas Trading Co. Drug Store owns the following subsidiaries:

Company's name	Ownership % as at		Ownership % as at 31 December 2024	Activity
	30 June 2025	2024		
United Purity Pharmaceutical Company*	-	99%	--	Sales agent for drugs, wholesale of medical devices, equipment and supplies and scientific devices, pharmacies', pharmaceutical warehouse, retail of medical devices, equipment and supplies.

* During the year ended 31 December 2024, Girgas signed a sale purchase agreement (“Girgas” or the “Seller”) with Nada Al Hayat Medical Company – Holding (“Nada” or the “Buyer”) for the sale of United Purity Pharmaceutical Company dated 25 August 2024.

Accordingly comparative figures in this interim financial information have been re-presented to present it as discontinued operations.

2. BASIS OF PREPARATION

Statement of Compliance

These interim condensed consolidated financial statements have been prepared in accordance with the International Accounting Standard (IAS 34) "Interim Financial Reporting" that is endorsed in the Kingdom of Saudi Arabia and other standards and pronouncements that are endorsed by the Saudi Organization for Chartered and Professional Accountants (SOCPA) and should be read in conjunction with the Group's last annual consolidated financial statements for the year ended 31 December 2024.

These interim condensed consolidated financial statements do not include all the information and disclosures required for a complete set of consolidated financial statements, however, accounting policies and selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance since 31 December 2024.

The interim period is considered as an integral part of the full financial year, however, the results of operations for the interim periods may not be a fair indication of the results for the full-year operations.

Preparation of Interim Condensed Consolidated Financial Statements

The material accounting policies adopted in the preparation of these interim condensed consolidated financial statements have been consistently applied to all the periods presented unless otherwise stated.

The preparation of these interim condensed consolidated financial statements requires the use of certain critical accounting estimates. It also requires the Group's management to exercise judgment in applying the Group's accounting policies.

The interim condensed consolidated financial statements have been prepared on a historical cost basis except for employees' defined benefits obligations, which are measured using the projected unit credit method.

Furthermore, these interim condensed consolidated financial statements are prepared using the accrual basis of accounting and the going concern basis.

Basis of Consolidation

The interim condensed consolidated financial statements comprise the interim condensed financial statements of the Company and subsidiaries controlled by the Company (collectively referred to as Group). Subsidiaries' interim condensed financial statements are prepared for the same reporting period as that of the Company, using consistent accounting policies.

Subsidiaries are the companies controlled by the Group. The Group controls an investee if, and only if, the Group has:

- Power over the investee (i.e. existing rights that give it the current ability to direct the relevant activities of the investee).
- Exposure or rights to variable returns from its involvement with the investee.
- The ability to use its power over the investee to affect its returns.

The Group re-assesses whether or not it controls the investee, if facts and circumstances indicate that there is a change to one or more of the control's elements mentioned above.

SCIENTIFIC AND MEDICAL EQUIPMENT HOUSE COMPANY
(A SAUDI JOINT STOCK COMPANY)
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
FOR THE THREE AND SIX-MONTH PERIOD ENDED 30 JUNE 2025 (CONTINUED)

2. BASIS OF PREPARATION (CONTINUED)

Basis of Consolidation (continued)

In general, there is an assumption that a majority of voting rights results in control. To support this presumption, when the Group has less than a majority of voting rights or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over an investee, including:

- The contractual arrangement(s) with the other vote holders of the investee
- Rights arising from other contractual arrangements
- The Group's voting rights and potential voting rights

Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. Balances between the Company and its subsidiaries, and any unrealised income and expenses arising from intra-group transactions, are eliminated in preparing the interim condensed consolidated financial statements.

Functional and Presentation Currency

The interim condensed consolidated financial statements are presented in Saudi Riyals (SAR), which is the Group's functional currency.

3. USE OF JUDGMENTS AND ESTIMATES

In preparing these interim condensed consolidated financial statements, management has made judgments and estimates that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Judgements and estimates are continually evaluated based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. In the future, actual results may differ from these estimates and assumptions.

The significant judgements made by the management in applying the Group's material accounting policies and the primary sources of estimating the unreliability were the same as those described in the last annual consolidated financial statements.

4. MATERIAL ACCOUNTING POLICY INFORMATION

The accounting policies applied in preparing the interim condensed consolidated financial statements are consistent with those followed in preparing the Group's annual consolidated financial statements for the year ended 31 December 2024, except for the application of the new standards that became effective on 1 January 2025. The Group did not early adopt any standard, interpretation or amendment issued but not yet effective.

a) NEW CURRENTLY EFFECTIVE REQUIREMENTS

<u>New accounting standards or amendments:</u>	<u>Effective date</u>
Lack of Exchangeability – Amendments to IAS 21	1 January 2025

Management anticipates that these new standards, interpretations and amendments will be adopted in the consolidated financial statements for the period of initial application. Adoption of these new standards, interpretations and amendments may have no material impact on the consolidated financial statements of the Group in the period of initial application

b) FORTHCOMING IFRS REQUIREMENTS

<u>New accounting standards or amendments:</u>	<u>Effective date</u>
Classification and Measurement of Financial Instruments – Amendments to IFRS 9 and IFRS 7	1 January 2026
Contracts Referencing Nature-dependent Electricity – Amendments to IFRS 9 and IFRS 7	
Annual Improvements to IFRS Accounting Standards – Volume 11	
IFRS 18 Presentation and Disclosure in Financial Statements	1 January 2027
IFRS 19 Subsidiaries without Public Accountability: Disclosures	
Sale or Contribution of Assets between an Investor and its Associate or Joint Venture (Amendments to IFRS 10 and IAS 28)	Available for optional adoption/ effective date deferred indefinitely

SCIENTIFIC AND MEDICAL EQUIPMENT HOUSE COMPANY
(A SAUDI JOINT STOCK COMPANY)
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
FOR THE THREE AND SIX-MONTH PERIOD ENDED 30 JUNE 2025 (CONTINUED)

5. TRADE RECEIVABLES AND CONTRACT ASSETS

		(SAUDI RIYAL)	
		30 June 2025 (Unaudited)	31 December 2024 (Audited)
Trade receivables	5-A	560,738,466	457,411,050
Contract assets	5-B	153,255,986	153,095,687
		713,994,452	610,506,737
Allowance for expected credit losses	5-C	(24,193,533)	(23,358,035)
		689,800,919	587,148,702

5 -A Trade receivables

		(SAUDI RIYAL)	
		30 June 2025 (Unaudited)	31 December 2024 (Audited)
Trade receivables – Government and semi-government sector		494,710,804	403,014,947
Trade receivables – Private sector		65,358,783	54,024,372
Retentions		668,879	371,731
		560,738,466	457,411,050

5 -B Contract assets

It represents balances relating to the performance completed against operation and maintenance contracts and constructions projects that were not billed as of period / year end:

		(SAUDI RIYAL)	
		30 June 2025 (Unaudited))	31 December 2024 (Audited)
Operation and maintenance contracts		147,494,244	148,058,946
Construction projects		5,761,742	5,036,741
		153,255,986	153,095,687

5 -C Allowance for expected credit losses

The movement in the allowance for expected credit losses is as follows:

		(SAUDI RIYAL)	
		30 June 2025 (Unaudited)	31 December 2024 (Audited)
Balance at the beginning of the period / year		23,358,035	27,945,225
Provision/(reversal) for the period / year		847,217	(4,568,842)
Disposal of a subsidiary		-	(3,169)
Write off		(11,719)	(15,179)
Balance at the end of the period / year		24,193,533	23,358,035

6. RELATED PARTIES BALANCES AND TRANSACTIONS

The related parties represent the Group's shareholders, key management personnel and the entities owned or managed by these parties, as well as the entities that have control or joint control or have significant influence over these parties.

SCIENTIFIC AND MEDICAL EQUIPMENT HOUSE COMPANY
(A SAUDI JOINT STOCK COMPANY)
**NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
FOR THE THREE AND SIX-MONTH PERIODS ENDED 30 JUNE 2025 (CONTINUED)**
6. RELATED PARTIES BALANCES AND TRANSACTIONS (Continued)

The following is a summary of significant transactions that took place between the Group and related parties during the three-month and six-month periods ended 30 June:

Related party name	Relationship	Nature of transactions	Three-month period ended		Six-month period ended	
			30-Jun	30-Jun	30-Jun	30-Jun
			2025	2024	2025	2024
			(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
			SAR	SAR	SAR	SAR
Rawabi Marketing International Co.	Affiliate	Expenses paid on behalf of an Affiliate	41,185	82,030	121,190	225,540
		Rental income	216,000	216,000	432,000	432,000
		Revenue from construction	-	-	2,318,332	-
		Revenue from maintenance and operating contracts	905,375	1,265,028	1,929,908	2,553,742
Rawabi for Smart Services & Devices Co.	Affiliate	Purchases	948,750	948,750	1,897,500	1,897,500
National Company for Sulfur Products	Affiliate	Expenses paid on behalf of an Affiliate	144,242	164,177	352,102	371,147
		Revenue from maintenance and operating contracts	1,288,758	1,385,563	2,566,248	2,669,001
		Rental income	96,000	96,000	192,000	192,000
German Metal Surface Treatment Chemicals Co	Affiliate	Expenses paid on behalf of an Affiliate	10,486	7,631	243	29,885
		Rental income	66,000	66,000	132,000	132,000
		Maintenance and operating revenues	200,070	219,104	422,911	454,745
		Purchases	84,606	-	84,606	-
Dirat Al Amar Real Estate Co.	Affiliate	Expenses paid on behalf of an Affiliate	228,357	489,926	493,614	863,124
		Rent paid	231,075	172,046	1,635,272	1,550,368
		Revenue from maintenance and operating contracts	333,647	-	832,367	-
Uni Land for Trading Est.	Affiliate	Expenses paid on behalf of an Affiliate	487,069	-	787,406	-
		Purchases	1,287,835	-	1,965,145	-
Wareed Medical Industries Company	Affiliate	Revenue from construction contract	6,600,119	-	6,600,119	-

SCIENTIFIC AND MEDICAL EQUIPMENT HOUSE COMPANY
(A SAUDI JOINT STOCK COMPANY)

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
FOR THE THREE AND SIX-MONTH PERIOD ENDED 30 JUNE 2025 (CONTINUED)

6 (a). DUE FROM RELATED PARTIES

	(SAUDI RIYAL)	
	30 June 2025 (Unaudited)	31 December 2024 (Audited)
Rawabi Marketing International Company	21,600,912	19,941,318
Wareed Medical Industries Company	9,458,869	201,321
Dirat Al Amar Real Estate Company	2,290,902	2,600,193
Uni Land for Trading Establishment	1,619,254	2,796,993
National Company for Sulfur Products	110,351	-
	35,080,288	25,539,825

6 (b). DUE TO RELATED PARTIES

	(SAUDI RIYAL)	
	30 June 2025 (Unaudited)	31 December 2024 (Audited)
Rawabi for Smart Services & Devices Company	1,897,500	-
German Metal Surface Treatment Chemicals Co	129,453	-
	2,026,953	-

7. SHARE CAPITAL

The authorized, issued and fully paid share capital of the Company consists of 30 million shares of SAR 10 each (31 December 2024: 30 million shares of SAR 10 each).

8. BANK FACILITIES

The Group has obtained Islamic bank facilities from local banks in the form of term loans (Murabaha and Tawarruq). Balance outstanding as at period end from these facilities amounts to SAR 179.9 million (31 December 2024: SAR 193.5 million). These facilities were obtained in accordance with the conditions stated in the bank facilities' agreements. The following are the facilities details:

	(SAUDI RIYAL)	
	30 June 2025 (Unaudited)	31 December 2024 (Audited)
Short-term borrowings (a)	172,324,799	185,138,364
Long-term borrowings (b)	7,550,000	8,325,000
	179,874,799	193,463,364

(a) The movement of short-term borrowings is as follows:

	(SAUDI RIYAL)	
	30 June 2025 (Unaudited)	31 December 2024 (Audited)
Opening balance	185,138,364	319,543,993
Additions during the period /year	224,077,617	764,160,031
Paid during the period /year	(236,891,182)	(898,565,660)
Ending balance	172,324,799	185,138,364

(b) This represents the amount withdrawn from a long-term loan facility which has been obtained by a subsidiary from the Saudi Industrial Development Fund with a total value of SAR 6,200,000 as well as a long-term loan amounting to SAR 3,750,000 obtained by the subsidiary from Saudi Aramco Entrepreneurship "Waed" in order to finance projects in progress.

SCIENTIFIC AND MEDICAL EQUIPMENT HOUSE COMPANY

(A SAUDI JOINT STOCK COMPANY)

**NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
FOR THE THREE AND SIX-MONTH PERIOD ENDED 30 JUNE 2025 (CONTINUED)****8. BANK FACILITIES (Continued)**

The movement of the long-term borrowings is as follows:

	(SAUDI RIYAL)	
	30 June 2025 (Unaudited)	31 December 2024 (Audited)
Balance at the beginning of the period/year	8,325,000	9,575,000
Paid during the period/year	(775,000)	(1,250,000)
Balance at the end of the period/year	7,550,000	8,325,000
Current portion	1,650,000	1,550,000
Non-current portion	5,900,000	6,775,000

9. OTHER INCOME

	(SAUDI RIYAL)			
	Three-month period ended		Six-month period ended	
	30 June 2025 (Unaudited)	30 June 2024 (Unaudited)	30 June 2025 (Unaudited)	30 June 2024 (Unaudited)
Compensation from Human Resources Development Fund	2,827,227	2,046,013	4,031,133	6,701,389
Rental income (note 6)	378,000	378,000	756,000	756,000
Gain/(Loss) on disposal of property, plant and equipment	213,992	(48,246)	217,899	(506,070)
Loss on terminated leases contracts	-	-	-	(148,582)
Others, net*	963,838	83,885	963,838	690,291
	4,383,057	2,459,652	5,968,870	7,493,028

*Others include an amount of SAR 963,839 as at 30 June 2025 resulting from reimbursement of certain costs resulting from the affirmation of the preliminary judgment by the Third Circuit of the Court of Appeals at the Commercial Court in Riyadh, whereby the Court issued the final ruling obligating the National Unified Procurement Company for Drugs, Medical Devices and Supplies (NUPCO) to pay Protecta Vision Company (a subsidiary) to pay a total of SAR 61,203,458, consisting of SAR 59,739,620 as the value of inventory, SAR 135,000 as expert fees, SAR 500,000 as attorney's fees, and SAR 828,838 as warehouse rent and insurance. The amount included under "Others, net" pertains solely to the reimbursement of expert fees SAR 135,000, and SAR 828,838 as warehouse rent and insurance.

10. BASIC AND DILUTED EARNINGS PER SHARE

The earnings per share is calculated based on the net profit for the period attributable to the Company's shareholders on the basis of the weighted average number of outstanding shares during that period, which amounted to 30 million (2024: 30 million shares). The diluted earnings per share is the same as the basic earnings per share as the Group does not have any issued dilutive instruments.

11. COMMITMENTS AND CONTINGENCIES**Commitments and guarantees:**

The Group has commitments in the form of letters of credit as of 30 June 2025 amounting to SAR 20.7 million (31 December 2024: SAR 27 million) and contingent liabilities against the letters of guarantee as of 30 June 2025 amounting to SAR 322 million (31 December 2024: SAR 329.4 million).

Legal claim contingency:

2025, one of the Group customers, a government entity, deducted SR 14.6 million from the payments of current ongoing projects with the Group. These deductions were for a service contract that was executed between years 2013 to 2019 and are made against alleged breaches of contract terms with respect to the provision of the aforementioned services. The Group has initiated legal proceedings against this and the latest court session is scheduled for 20 August 2025. The case remains open and under continuous legal follow-up by the Group. Management has assessed the likelihood of an unfavorable outcome and, based on in-house legal advice, recognized an estimated liability of SR 3 million in the interim condensed consolidated financial statements.

SCIENTIFIC AND MEDICAL EQUIPMENT HOUSE COMPANY

(A SAUDI JOINT STOCK COMPANY)

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
FOR THE THREE AND SIX-MONTH PERIOD ENDED 30 JUNE 2025 (CONTINUED)
12. SEGMENT INFORMATION

The operating segments are recorded in a manner consistent with the internal reporting structure. The Management monitors the operating results of its segments independently for the purpose of performance evaluation. For management purposes, the Group is organized into business units based on its products and services and has five reportable segments and all the operations are carried out in the Kingdom of Saudi Arabia, the segments are as follows:

-Operation and maintenance: Deals with supply of medical and non-medical staff and medical equipment maintenance services.

-Medical equipment sales and post-sale maintenance services revenue: Supplier of medical equipment and related spare parts.

-Construction segment: Deals in general contracting of buildings, roads, electrical, electronic and mechanical works.

- Meat and food segment: Supplies refrigerated food warehouses, wholesale of food and drinks.

-Medicine and medical supplies: Supplies segment is involved in wholesale and retail trade in medical supplies through pharmacies.

No operating segments have been aggregated to form the above reportable operating segments.

FOR THE SIX-MONTH PERIOD ENDED 30 JUNE 2025 (unaudited)

	Operation and maintenance	Medical equipment sales and post-sale maintenance services revenue	Construction	Meat and food	Medicine and medical supplies	Eliminations	Total
External Customers	352,977,176	95,485,551	25,083,016	10,606,132	10,116,315	-	494,268,190
Inter Segment	10,602,321	-	-	758,579	-	(11,360,900)	-
Revenues	363,579,497	95,485,551	25,083,016	11,364,711	10,116,315	(11,360,900)	494,268,190
Cost of Sales	(324,823,353)	(70,656,953)	(19,633,528)	(10,808,931)	(7,198,881)	11,360,900	(421,760,746)
Gross profit	38,756,144	24,828,598	5,449,488	555,780	2,917,434	-	72,507,444
Selling and marketing expenses	(695,012)	(9,882,472)	-	(100,949)	(361,051)	-	(11,039,484)
General and administrative expenses	(24,772,372)	(1,127,364)	(2,387,988)	(1,128,311)	(970,504)	33,750	(30,352,789)
Reversal / (Provision) for expected credit losses	1,102,783	(1,200,000)	-	(150,000)	(600,000)	-	(847,217)
Operation Profit / (loss)	14,391,543	12,618,762	3,061,500	(823,480)	985,879	33,750	30,267,954
Other income	5,044,008	963,839	-	-	-	(38,977)	5,968,870
Net profit / (loss)	14,377,661	10,893,567	3,012,438	(1,754,144)	409,023	(7,869,846)	19,068,699

FOR THE SIX-MONTH PERIOD ENDED 30 JUNE 2024 (unaudited)

	Operation and maintenance	Medical equipment sales and post-sale maintenance services revenue	Construction	Meat and food	Medicine and medical supplies	Eliminations	Total
External Customers	353,509,303	41,519,935	24,804,267	7,975,188	3,811,331	-	431,620,024
Inter Segment	8,706,066	618,709	-	-	-	(9,324,775)	-
Revenues	362,215,369	42,138,644	24,804,267	7,975,188	3,811,331	(9,324,775)	431,620,024
Cost of Sales	(310,932,482)	(30,193,495)	(17,722,472)	(7,048,022)	(2,745,736)	9,324,775	(359,317,432)
Gross profit	51,282,887	11,945,149	7,081,795	927,166	1,065,595	-	72,302,592
Selling and marketing expenses	(101,580)	(8,177,346)	-	-	-	-	(8,278,926)
General and administrative expenses	(24,060,744)	(705,147)	(2,879,255)	(1,402,285)	(1,292,981)	39,718	(30,300,694)
Reversal / (Provision) for expected credit losses	1,179,204	(300,000)	-	82,821	-	-	962,025
Operation Profit / (loss)	28,299,767	2,762,656	4,202,540	(392,298)	(227,386)	39,718	34,684,997
Other income	7,532,746	-	-	-	-	(39,718)	7,493,028
Net profit / (loss)	9,303,376	(1,670,180)	4,178,683	(1,146,217)	(6,745,750)	11,732,997	15,652,909

SCIENTIFIC AND MEDICAL EQUIPMENT HOUSE COMPANY

(A SAUDI JOINT STOCK COMPANY)

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

FOR THE THREE AND SIX-MONTH PERIOD ENDED 30 JUNE 2025 (CONTINUED)

12. SEGMENT INFORMATION (CONTINUED)
FOR THE THREE-MONTH PERIOD ENDED 30 JUNE 2025 (unaudited)

	Operation and maintenance	Medical equipment sales and post-sale maintenance services revenue	Construction	Meat and food	Medicine and medical supplies	Eliminations	Total
External Customers	165,206,556	79,458,327	11,788,928	6,205,050	9,377,317	-	272,036,178
Inter Segment	5,026,172	-	-	239,048	-	(5,265,220)	-
Revenues	170,232,728	79,458,327	11,788,928	6,444,098	9,377,317	(5,265,220)	272,036,178
Cost of Sales	(156,589,949)	(60,131,035)	(8,846,288)	(6,271,077)	(6,720,466)	5,265,220	(233,293,595)
Gross profit	13,642,779	19,327,292	2,942,640	173,021	2,656,851	-	38,742,583
Selling and marketing expenses	(483,847)	(4,962,793)	-	(56,424)	(154,852)	-	(5,657,916)
General and administrative expenses	(12,677,713)	(556,225)	(1,314,894)	(692,351)	(510,984)	16,875	(15,735,292)
Provision for expected credit losses	(300,000)	(600,000)	-	(150,000)	(300,000)	-	(1,350,000)
Operation Profit / (loss)	181,219	13,208,274	1,627,746	(725,754)	1,691,015	16,875	15,999,375
Other income	3,438,674	963,839	-	-	-	(19,456)	4,383,057
Net profit / (loss)	8,244,670	12,974,287	1,603,838	(1,205,095)	1,402,240	(11,245,296)	11,774,644

FOR THE THREE-MONTH PERIOD ENDED 30 JUNE 2024 (unaudited)

	Operation and maintenance	Medical equipment sales and post-sale maintenance services revenue	Construction	Meat and food	Medicine and medical supplies	Eliminations	Total
External Customers	178,670,651	19,491,894	12,862,828	3,044,910	1,373,971	-	215,444,254
Inter Segment	4,630,307	340,977	-	-	-	(4,971,284)	-
Revenues	183,300,958	19,832,871	12,862,828	3,044,910	1,373,971	(4,971,284)	215,444,254
Cost of Sales	(158,362,582)	(14,262,339)	(8,908,230)	(2,769,494)	(1,173,246)	4,971,284	(180,504,607)
Gross profit	24,938,376	5,570,532	3,954,598	275,416	200,725	-	34,939,647
Selling and marketing expenses	(78,000)	(3,999,971)	-	-	-	-	(4,077,971)
General and administrative expenses	(11,678,567)	(348,890)	(1,552,056)	(945,530)	(621,142)	19,778	(15,126,407)
Reversal for expected credit losses	1,479,204	300,000	-	72,633	-	-	1,851,837
Operation Profit / (loss)	14,661,013	1,521,671	2,402,542	(597,481)	(420,417)	19,778	17,587,106
Other income	2,482,495	-	-	-	-	(22,843)	2,459,652
Net profit / (loss)	4,935,915	(1,989,901)	2,411,972	(1,000,799)	(4,052,855)	7,049,622	7,353,954

13. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

The Group's financial instruments included in the interim condensed consolidated statement of financial position include cash and cash equivalents, trade receivables, contract assets, other debit balances, due from / to related parties, short and long-term loans, trade payables, and other credit balances.

Currency risks

Currency risks are the risk arising from the fluctuation in the value of financial instruments due to changes in foreign exchange rates. The risks are managed by periodic monitoring of the relevant exchange rates.

Credit risks

Credit risks are the risk that a party to a financial instrument will fail to discharge an obligation and cause the Group to incur a financial loss. The Group's credit risks arise primarily from its dealings with government agencies. The government agencies are part of the government of the Kingdom of Saudi Arabia which has a strong credit rating.

The Group's management monitors the unpaid balances, and, when appropriate, trade receivables is stated at net, after deducting the provision for expected credit losses. Cash is placed with banks with investment grade credit ratings.

Commission rate risks

Commission rate risks are the risk that the value of financial instruments will fluctuate due to changes in commission rates prevailing in the market. The Group is exposed to commission rate risk on its commission-bearing financial liabilities as of 30 June 2025 and 31 December 2024.

Liquidity risks

This is the risk that the Group will not be able to secure the necessary liquidity to meet commitments related to financial instruments. Liquidity risk may result from the inability to sell a financial asset quickly at a value close to its fair value. Liquidity risk is managed through periodic monitoring to ensure that sufficient liquidity is available to meet any future commitments.

14. FAIR VALUE OF FINANCIAL INSTRUMENTS

Fair value is the amount with which an asset is exchanged, or a liability is settled between parties who have knowledge and desire to do so with fair transaction conditions. Management believes that the fair values of the Group's financial assets and liabilities are not materially different from their carrying values. As of 30 June 2025, and 31 December 2024, the Group has no financial instruments measured at fair value.

15. SUBSEQUENT EVENTS

The management believes that there are no significant subsequent events that require disclosure or adjustment to these interim condensed consolidated financial statements.

16. APPROVAL OF THE INTERIM FINANCIAL INFORMATION

The Interim Financial information has been approved by the Board of Directors on 16 Safar 1447 AH corresponding to 10 August 2025.